Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Companies & Market Trends Insight 2023 Report Highlights:
- Global Tetraspecific Clinical Trials Landscape Insight
- Global Tetraspecific Ongoing Clinical Trials By Company, Country, Indication & Phase
- Tetraspecific Antibodies Proprietary Technologies By Company
- Current Clinical Development & Future Commercialization Outlook
- Tetraspecific Antibodies Mono & Combination Therapeutic Approaches
- Competitive Landscape
With scientific progress, pharmaceutical research and development activities have led to the generation of new innovative and novel therapies which have created a new era in drug development. Continuous innovation in the field has enabled the introduction of tetraspecific antibodies which are offering promising results and are leading to breakthrough in field of antibodies. The therapeutic impact of tetraspecific antibody strategy is currently being investigated in cancer and preclinical studies of several candidates have provided with promising results.
Although tetraspecific antibodies have been a fairly new class of immunotherapies which have only come under attention over the past years, their specificity towards multiple cancer targets has attracted considerable attention. These tetraspecific antibodies are designed to target four different targets simultaneously, representing a major shift in the multispecific antibody market as they offer several advantages over traditional monoclonal antibody based therapies.
For a long time, immune checkpoint proteins have been targeted so as to generate an immune response. This method has shown immense success in clinical studies as well had a huge impact on global sales. However, after the discovery of co-stimulatory receptors, researchers from several pharmaceutical companies all over the world have initiated their investigation into developing drugs that could activate such receptors. With tetraspecific antibodies, the idea of combination both these approaches become feasible that could result in boosting the anti-tumor response of the body.
Several co-stimulatory receptors have emerged as a promising target for T cell co-stimulation related cancer immunotherapy. Currently, ongoing clinical and pre-clinical studies are determining the efficacy of such co-stimulatory receptors. Moreover, tetraspecific antibodies have also incorporated this approach of co-stimulation. Candidates under clinical trials like GNC-035, upon administration binds to 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) and other targets. Another candidate, GNC-039 molecule can bind CD3 and EGFR-vIII to redirect T cell cytotoxicity toward specified cancer indication defined by EGFR-vIII expression.
Mounting evidence from preclinical and clinical studies has pointed that multiple targeting by tetraspecific antibodies could further improve clinical outcomes and become attractive novel modalities in immuno-oncology therapies. Several pharmaceutical industries are actively pursuing the development of tetraspecific antibodies, with candidates being in pre-clinical studies and some also moving forward to in-human clinical trials.
Additionally, several pharmaceutical companies have developed proprietary technology platforms enabling better production of tetraspecific antibody formats and their targeting. For instance, For instance, Innate pharma has developed a propriety platform ANKET (Antibody Based NK Cell Engager Therapeutic) for developing next generation, multi specific NK cell engagers. This versatile technology has allowed the incorporation of four distinct targets while also engaging NK cells to stimulate robust immune response.
For now, China has a lead in the development of tetraspecific antibodies. China’s Baili Pharmaceuticals and its US based subsidiary, SystImmune has a total of three tetraspecific candidate sin its clinical pipeline. All the three candidates are targeting different cancer indications and preclinical studies of them have showed promising results. The development of tetraspecific antibodies has offered Baili Pharmaceuticals and SystImmune to stand out in the crowded market of multispecific antibodies.
There are several other companies which are also working in this emerging market of tetraspecific antibody; Innate Pharma, Modex Therapeutics, Sanofi an Opko Health. The growing interest in tetraspecific antibodies indicates their potential as a novel approach and the possibility of providing improved cancer treatment options. Nevertheless, the approach is at its nascent stage but in the coming few years, regulatory approvals are foreseeable with positive results.
This report provides insight on proprietary technologies, comprehensive study on the ongoing clinical and preclinical candidates while also providing the detailed mechanism of action of tetraspecific antibodies. The report also includes assessment of the current market landscape, providing information about the tetraspecific mechanism of action, formats and different therapeutic approaches adopted.